Nasal samples are nasal samples. Having shares in the company doesn't change the viral load in your samples.
This is for the first time where shareholders has the ability to expedite things, so if we can all follow the rules of the clinical trial to the tee, I don't see why shareholders cannot/shouldn't take part in the trial.
300 samples is nothing to sneeze at, especially if the company isn't trying that hard to push people to the trial...
ADO Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)